Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients

Abstract

Introduction : IL-10 serum levels were measured before chemotherapy, on completion of therapy, and at follow-up by means of a commercially available enzyme-linked immunoassay. Methods : Sixty consecutive patients,stage III or IV NSCLC undergoing conventional platinum-based regimens. Results : Elevated levels of serum IL-10 were found in cancer patients with respect to healthy control subjects (15.2 vs 7.2 pg/mL; p Conclusions : In conclusion, this study shows that the measurement of pretreatment IL-10 serum levels is of independent prognostic utility in patients with NSCLC and may be useful for detection of disease progression.